1. Home
  2. IDYA vs PARR Comparison

IDYA vs PARR Comparison

Compare IDYA & PARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$27.99

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Par Pacific Holdings Inc.

PARR

Par Pacific Holdings Inc.

HOLD

Current Price

$63.17

Market Cap

3.2B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
PARR
Founded
2015
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Integrated oil Companies
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.2B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
IDYA
PARR
Price
$27.99
$63.17
Analyst Decision
Strong Buy
Buy
Analyst Count
16
6
Target Price
$52.86
$70.17
AVG Volume (30 Days)
1.4M
1.3M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
61.90
1313.56
EPS
N/A
1.10
Revenue
$218,710,000.00
$2,443,066,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$201.05
$3.78
P/E Ratio
N/A
$58.58
Revenue Growth
3024.43
30.99
52 Week Low
$17.17
$18.78
52 Week High
$39.28
$70.39

Technical Indicators

Market Signals
Indicator
IDYA
PARR
Relative Strength Index (RSI) 36.30 51.07
Support Level $26.05 $34.55
Resistance Level $28.05 $68.89
Average True Range (ATR) 1.15 3.35
MACD -0.12 -0.51
Stochastic Oscillator 7.68 50.74

Price Performance

Historical Comparison
IDYA
PARR

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About PARR Par Pacific Holdings Inc.

Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.

Share on Social Networks: